Publications by authors named "Julie Prevost"

Claim this Profile
M
Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis.
Yi Chao Foong, Daniel Merlo, Melissa Gresle, Katherine Buzzard, Dana Horakova, Julie Prevost

J Neurol Neurosurg Psychiatry· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistent progression independent of relapse activity in multiple sclerosis.
Chao Zhu, Zhen Zhou, Tomas Kalincik, Izanne Roos, Katherine Buzzard, Julie Prevost

Brain Commun· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis.
Tomas Kalincik, Sifat Sharmin, Izanne Roos, Mark S Freedman, Harold Atkins, Julie Prevost

Brain· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data.
Ashkan Pirmani, Edward De Brouwer, Ádám Arany, Martijn Oldenhof, Antoine Passemiers, Julie Prevost

NPJ Digit Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.
Jannis Müller, Sifat Sharmin, Johannes Lorscheider, Serkan Ozakbas, Rana Karabudak, Julie Prevost

JAMA Neurol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.
Johannes Lorscheider, Alessio Signori, Suvitha Subramaniam, Pascal Benkert, Sandra Vukusic

J Neurol Neurosurg Psychiatry· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Explainable time-to-progression predictions in multiple sclerosis.
Robbe D'hondt, Klest Dedja, Sofie Aerts, Bart Van Wijmeersch, Tomas Kalincik, Julie Prevost

Comput Methods Programs Biomed· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study.
Jannis Müller, Sifat Sharmin, Johannes Lorscheider, Dana Horakova, Eva Kubala Havrdova, Julie Prevost

CNS Drugs· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis.
Simona Toscano, Tim Spelman, Serkan Ozakbas, Raed Alroughani, Clara G Chisari, Julie Prevost

Neurotherapeutics· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies.
Wei Z Yeh, Anneke Van Der Walt, Olga G Skibina, Tomas Kalincik, Raed Alroughani, Julie Prevost

Neurol Neuroimmunol Neuroinflamm· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
Izanne Roos, Sifat Sharmin, Charles Malpas, Serkan Ozakbas, Jeannette Lechner-Scott

Mult Scler· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
Ying Li, Alice Saul, Bruce Taylor, Anne-Louise Ponsonby, Steve Simpson-Yap, Julie Prevost

J Neurol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of treatment switching in the Big Multiple Sclerosis Data Network.
Tim Spelman, Melinda Magyari, Helmut Butzkueven, Anneke Van Der Walt, Sandra Vukusic, Julie Prevost

Front Neurol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
Sifat Sharmin, Izanne Roos, Steve Simpson-Yap, Charles Malpas, Marina M Sánchez, Julie Prevost

Brain· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disability accrual in primary and secondary progressive multiple sclerosis.
Sam Harding-Forrester, Izanne Roos, Ai-Lan Nguyen, Charles B Malpas, Ibrahima Diouf, Julie Prevost

J Neurol Neurosurg Psychiatry· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.
Chao Zhu, Tomas Kalincik, Dana Horakova, Zhen Zhou, Katherine Buzzard, Julie Prevost

JAMA Neurol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
Cyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, Eva Kubala Havrdova, Dana Horakova, Julie Prevost

Mult Scler· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis.
Ibrahima Diouf, Charles B Malpas, Sifat Sharmin, Izanne Roos, Dana Horakova, Julie Prevost

Eur J Neurol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness in multiple sclerosis: A methodological comparison.
Izanne Roos, Ibrahima Diouf, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova, Julie Prevost

Mult Scler· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of relapse activity when switching to cladribine for multiple sclerosis.
Michael Zhong, Anneke van der Walt, Mastura Monif, Suzanne Hodgkinson, Sara Eichau, Julie Prevost

Mult Scler· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network.
Alessio Signori, Johannes Lorscheider, Sandra Vukusic, Maria Trojano, Pietro Iaffaldano, Julie Prevost

J Neurol Neurosurg Psychiatry· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
Chao Zhu, Zhen Zhou, Izanne Roos, Daniel Merlo, Tomas Kalincik, Julie Prevost

J Neurol Neurosurg Psychiatry· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
Izanne Roos, Charles Malpas, Emmanuelle Leray, Romain Casey, Dana Horakova, Julie Prevost

Neurology· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Confirmed disability progression as a marker of permanent disability in multiple sclerosis.
Sifat Sharmin, Francesca Bovis, Charles Malpas, Dana Horakova, Eva Kubala Havrdova, Julie Prevost

Eur J Neurol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study.
Marianna Vitkova, Ibrahima Diouf, Charles Malpas, Dana Horakova, Eva Kubala Havrdova, Julie Prevost

Neurology· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis